News
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...
Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...
Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results